Killen Group’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Killen Group’s Portfolio OSIR Stock Details OSIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$228K	Buy	40,000 +9,000	+29%	+$62.9K	0.03%	108
2015 Q4	$322K	Buy	31,000 +1,000	+3%	+$13.6K	0.03%	100
2015 Q3	$554K	Sell	30,000 -4,600	-13%	-$88.8K	0.05%	90
2015 Q2	$673K	Hold	34,600	–	–	0.05%	88
2015 Q1	$608K	Hold	34,600	–	–	0.04%	94
2014 Q4	$553K	Hold	34,600	–	–	0.04%	94
2014 Q3	$436K	Hold	34,600	–	–	0.02%	110
2014 Q2	$540K	Hold	34,600	–	–	0.03%	107
2014 Q1	$454K	Hold	34,600	–	–	0.02%	107
2013 Q4	$556K	Buy	34,600 +4,600	+15%	+$73.3K	0.03%	108
2013 Q3	$499K	Buy	30,000 +10,000	+50%	+$148K	0.03%	106
2013 Q2	$201K	Buy	+20,000	New	+$210K	0.01%	108

Other funds holding OSIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Killen Group's OSIR Position: Q1 2016 in Review

Killen Group increased its Osiris Therapeutics, Inc. Common Stock (OSIR) stake by 29% in Q1 2016, buying an estimated $62.9K and bringing the position to 40,000 shares worth $228K. The position accounts for 0.03% of the portfolio, ranked #108.

Killen Group first reported a position in OSIR in Q2 2013 and has held it in 12 quarters since. The position peaked at $673K in Q2 2015. 80 funds tracked by Wall St. Rank hold OSIR as of Q1 2016.

Killen Group held 40,000 shares of Osiris Therapeutics, Inc. Common Stock worth $228K as of Q1 2016.
Killen Group bought 9,000 Osiris Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $62.9K.
Osiris Therapeutics, Inc. Common Stock made up 0.03% of Killen Group's portfolio in Q1 2016, its #108 holding.
Killen Group first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 12 quarters since.
Killen Group's Osiris Therapeutics, Inc. Common Stock position peaked at $673K in Q2 2015.
80 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Killen Group's 13F filing for Q1 2016, filed 27 Apr 2016.